Rheumatology Network's Top 5: April 16, 2021

April 16, 2021

Take 5 minutes to catch up on Rheumatology Network's highlights from the week ending April 16, 2021.

Total Glucosides of Paeony Reduces Leukopenia, Hepatic Adverse Effect From Some RA Drugs

In this systematic review and meta-analysis, investigators aimed to evaluate the clinical safety of total glucosides of paeony (TGP) adjuvant therapy in the treatment of rheumatoid arthritis (RA).

Click the image to view the story.

Brad Marder, MD: Pegloticase Therapy in Gout Patients Undergoing Dialysis

This week, Rheumatology Network sat down Brad Marder, MD, co-author of the study, Pegloticase Therapy in Gout Patients Undergoing Dialysis: A USRDS Database Study. Data suggests that pegloticase is successful in the treatment of dialysis patients with uncontrolled gout with potentially lower ESA dose requirements after treatment.

Click the image to view the story.

Females at Greater Risk for Developing Psoriatic Arthritis in Recent Years

While incidence rates remained stable throughout the study period, incidence rates in females increased 3% per year between 2000 and 2017. The increase was seen primarily in women 40-49 and 50-59.

Click the image to view the story.

Guselkumab Effective in Treating Enthesitis in Psoriatic Arthritis

Patients with psoriatic arthritis (PsA) treated with guselkumab resulted in higher percentages of resolved enthesitis by Week 24 and maintained those results through 1 year when compared with a placebo.

Click the image to view the story.

Lauren Gelman: What is CreakyJoints?

As a part of our partnership with CreakyJoints, Rheumatology Network sat down with Lauren Gelman, Director of Editorial Services, for the Global Healthy Living Foundation. CreakyJoints is a support, education, advocacy, and research organization for people living with arthritis and rheumatic disease.

Click the image to view the story.